Cytek Biosciences

Cytek Biosciences, Inc. is a life sciences technology company engaged in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in December 2014 and is headquartered in Fremont, CA.

Earnings data Q1 2024

Cytek Biosciences reports mixed Q1 results, focuses on growth opportunities

Cytek Biosciences reported mixed financial results with revenue growth but declining organic revenue. The company faces challenges from industry headwinds but is confident in its leadership position and is focused on growth opportunities in key markets.

Cytek Biosciences reports robust Q2 earnings and anticipates FDA submissions

Cytek Biosciences delivered strong financial performance in Q2 2023, driven by growth in the U.S. market and the successful integration of the Luminex business. While facing challenges in Europe, the company remains optimistic about future opportunities, including FDA submissions and partnerships for clinical applications.

Cytek Biosciences reports 19% revenue growth in Q3 2023

Cytek Biosciences demonstrated solid revenue growth, particularly driven by the Luminex acquisition, but faced challenges with extended sales cycles and conservative customer spending patterns. The company's focus on clinical opportunities, successful manufacturing transition, and strong cash position position it well for future growth, despite anticipated softness in the top line for 2024.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in 1992 and is headquartered in Fremont, CA.

The heavy selling pressure might have exhausted for Cytek Biosciences (CTKB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Cytek Biosciences (CTKB) Loses -7.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The consensus price target hints at a 47.6% upside potential for Cytek Biosciences (CTKB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Cytek Biosciences (CTKB) Could Rally 47.61%: Here's is How to Trade

Crescent Point Energy

Crexendo, Inc.

High Tide

SIGA Technologies

CXDO, HITI, SIGA, CPG and CTKB have been added to the Zacks Rank #1 (Strong Buy) List on April 2, 2023.

New Strong Buy Stocks for April 2nd

Cytek Biosciences is a leading cellular analysis instrument maker with a focus on the Aurora flow cytometry platform. Despite a downturn in the healthcare market, Cytek has maintained revenue growth above 15% since IPO. Cytek's technological advantage, broadening ecosystem, and potential in the clinical and biopharma space contribute to the leading financials and positive outlook.

Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader

Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company effective immediately.

Cytek® Biosciences Names William McCombe Chief Financial Officer

Cytek Biosciences has opened a 50,000-square-foot facility in Wuxi, China to meet the growing worldwide demand for comprehensive cell analysis solutions

Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions

Cytek Biosciences, Inc. (CTKB) Q4 2023 Earnings Call Transcript

FREMONT, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2023.

Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

Cytek Biosciences, Inc. (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Cytek Biosciences, Inc. (CTKB) Q4 Earnings Expected to Decline

FREMONT, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.

Cytek Biosciences to Participate in Upcoming Investor Conferences

FREMONT, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28th, 2024. The company's management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.

Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Cytek Biosciences has signed an agreement with The Centre for Genomic Regulation and the Pompeu Fabra University to accelerate scientific discoveries.

Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries

Cytek Biosciences, Inc. (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Cytek Biosciences, Inc. (CTKB) Surges 10.3%: Is This an Indication of Further Gains?

FREMONT, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2023.

Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results

FREMONT, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare Conference

The new Cytek Orion reagent cocktail preparation system simplifies & accelerates laboratory workflow, assures consistent experimental results & saves time.

Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry

AMC Networks

Century Aluminum

3D Systems

Hudson Pacific Properties

Harmony Biosciences Holdings

PRA Group

Proto Labs

Sonos

Triumph Group

Small stocks are blasting past the S&P 500 — and investors are loading up on a handful of them fast.

Small Stocks Are On A Tear — Investors Race To Buy These 10

Agiliti Inc

AdaptHealth Corp

Digital Turbine

Clearfield

Enphase Energy

Lumen Technologies

Moderna

SunPower

Vir Biotechnology

According to a study published this summer in The Review of Financial Studies, these vulnerable stocks are the ones that are most difficult to borrow and then sell short.

Why these stocks could lose money even if the market gains

FREMONT, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, New York.

Cytek Biosciences to participate in the Piper Sandler 35th Annual Healthcare Conference

Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO Patrik Jeanmonod - CFO Conference Call Participants David Westenberg - Piper Sandler Steven Mah - TD Cowen Matthew Sykes - Goldman Sachs Andrew Cooper - Raymond James Operator Good day and thank you for standing by. Welcome to the Cytek Biosciences Third Quarter 2023 Earnings Conference Call.

Cytek Biosciences, Inc. (CTKB) Q3 2023 Earnings Call Transcript

The Cytek® Aurora™ CS system has been selected as the “Cell Sorting Product of the Year” in the third annual BioTech Breakthrough Awards program.

Cytek® Aurora™ CS System Wins BioTech Breakthrough Award for ‘Cell Sorting Product of the Year'

FREMONT, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2023.

Cytek Biosciences Reports Third Quarter 2023 Financial Results

Earnings Preview: Cytek Biosciences, Inc. (CTKB) Q3 Earnings Expected to Decline

FREMONT, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the third quarter 2023 after market close on Tuesday, November 7th, 2023. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Cytek Biosciences to Report Third Quarter 2023 Financial Results on November 7, 2023

AdvanSix

ERO Copper Corp

ASIX, CTKB and ERO have been added to the Zacks Rank #5 (Strong Sell) List on October 19, 2023.

News for Cytek Biosciences Stock (CTKB)